NCT03070002View on ClinicalTrials.gov

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

October 19, 2017

Primary Completion Date

March 6, 2018

Study Completion Date

April 24, 2018

Conditions
Breast Carcinoma Metastatic in the BoneCirculating Tumor Cell CountEstrogen Receptor PositiveHER2/Neu NegativeProgesterone Receptor PositiveStage IV Breast Cancer
Interventions
BIOLOGICAL

Denosumab

Given SC

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (2)

60045

Northwestern University- Lake Forest Hospital, Lake Forest

60611

Northwestern University, Chicago

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER